No Data
We Think Acrivon Therapeutics (NASDAQ:ACRV) Needs To Drive Business Growth Carefully
JonesTrading Maintains Acrivon Therapeutics(ACRV.US) With Buy Rating, Maintains Target Price $22
JonesTrading analyst Soumit Roy maintains $Acrivon Therapeutics(ACRV.US)$ with a buy rating, and maintains the target price at $22.According to TipRanks data, the analyst has a success rate of 26.0% a
Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
JMP Securities Maintains Acrivon Therapeutics(ACRV.US) With Buy Rating, Maintains Target Price $17
JMP Securities analyst Silvan Tuerkcan maintains $Acrivon Therapeutics(ACRV.US)$ with a buy rating, and maintains the target price at $17.According to TipRanks data, the analyst has a success rate of
Acrivon Therapeutics: A Buy Rating on Strong Clinical and Financial Prospects
Has Acrivon Therapeutics, Inc. (ACRV) Outpaced Other Medical Stocks This Year?
No Data